B-intervention	0	9	Neratinib
O	10	15	after
O	16	27	trastuzumab
O	27	28	-
O	28	33	based
O	34	42	adjuvant
O	43	50	therapy
O	51	53	in
O	54	62	patients
O	63	67	from
B-location	68	72	Asia
O	73	77	with
O	78	83	early
O	84	89	stage
O	90	94	HER2
O	94	95	-
O	95	103	positive
O	104	110	breast
O	111	117	cancer
O	117	118	.

O	119	122	Aim
O	122	123	:
O	124	126	To
O	127	135	evaluate
O	136	139	the
O	140	148	efficacy
O	149	152	and
O	153	159	safety
O	160	162	of
O	163	172	neratinib
O	173	175	as
O	176	184	extended
O	185	193	adjuvant
O	194	201	therapy
O	202	204	in
O	205	213	patients
O	214	218	from
O	219	223	Asia
O	224	229	based
O	230	232	on
O	233	244	exploratory
O	245	253	analyses
O	254	256	of
O	257	260	the
O	261	266	Phase
O	267	270	III
O	271	278	ExteNET
O	279	284	trial
O	284	285	.

O	286	294	Patients
O	295	296	&
O	297	304	methods
O	304	305	:
O	306	307	A
O	308	313	total
O	314	316	of
B-total-participants	317	321	2840
B-eligibility	322	327	women
I-eligibility	328	332	with
I-eligibility	333	338	early
I-eligibility	339	344	stage
I-eligibility	345	349	HER2
I-eligibility	349	350	-
I-eligibility	350	358	positive
I-eligibility	359	365	breast
I-eligibility	366	372	cancer
O	373	377	were
O	378	386	randomly
O	387	395	assigned
O	396	398	to
O	399	408	neratinib
O	409	412	240
O	413	415	mg
O	415	416	/
O	416	419	day
O	420	422	or
B-control	423	430	placebo
O	431	434	for
O	435	436	1
O	437	441	year
O	442	447	after
O	448	459	trastuzumab
O	459	460	-
O	460	465	based
O	466	474	adjuvant
O	475	482	therapy
O	482	483	.

O	484	491	Results
O	491	492	:
O	493	494	A
O	495	500	total
O	501	503	of
B-total-participants	504	507	341
O	508	516	patients
O	517	521	were
O	522	526	from
O	527	531	Asia
O	532	533	(
O	533	542	neratinib
O	542	543	,
O	544	545	n
O	546	547	=
B-intervention-participants	548	551	165
O	551	552	;
O	553	560	placebo
O	560	561	,
O	562	563	n
O	564	565	=
B-control-participants	566	569	176
O	569	570	)
O	570	571	.

B-outcome	572	573	2
I-outcome	573	574	-
I-outcome	574	578	year
I-outcome	579	587	invasive
I-outcome	588	595	disease
I-outcome	595	596	-
I-outcome	596	600	free
I-outcome	601	609	survival
I-outcome	610	615	rates
O	616	620	were
B-iv-bin-percent	621	623	92
I-iv-bin-percent	623	624	.
I-iv-bin-percent	624	625	8
O	626	629	and
B-cv-bin-percent	630	632	90
I-cv-bin-percent	632	633	.
I-cv-bin-percent	633	634	8
I-cv-bin-percent	634	635	%
O	636	640	with
O	641	650	neratinib
O	651	654	and
O	655	662	placebo
O	662	663	,
O	664	676	respectively
O	677	678	(
O	678	680	HR
O	680	681	:
O	682	683	0
O	683	684	.
O	684	686	70
O	686	687	;
O	688	690	95
O	690	691	%
O	692	694	CI
O	694	695	:
O	696	697	0
O	697	698	.
O	698	700	31
O	700	701	-
O	701	702	1
O	702	703	.
O	703	705	55
O	705	706	)
O	706	707	,
O	708	711	and
B-outcome	712	713	5
I-outcome	713	714	-
I-outcome	714	718	year
I-outcome	719	724	rates
O	725	729	were
B-iv-bin-percent	730	732	91
I-iv-bin-percent	732	733	.
I-iv-bin-percent	733	734	9
O	735	738	and
B-cv-bin-percent	739	741	87
I-cv-bin-percent	741	742	.
I-cv-bin-percent	742	743	2
I-cv-bin-percent	743	744	%
O	744	745	,
O	746	758	respectively
O	759	760	(
O	760	762	HR
O	762	763	:
O	764	765	0
O	765	766	.
O	766	768	57
O	768	769	;
O	770	772	95
O	772	773	%
O	774	776	CI
O	776	777	:
O	778	779	0
O	779	780	.
O	780	782	27
O	782	783	-
O	783	784	1
O	784	785	.
O	785	787	13
O	787	788	)
O	788	789	.

B-outcome	790	798	Diarrhea
O	799	802	was
O	803	806	the
O	807	811	most
O	812	818	common
O	819	826	adverse
O	827	832	event
O	833	837	with
O	838	847	neratinib
O	847	848	.

O	849	859	Conclusion
O	859	860	:
O	861	869	Extended
O	870	878	adjuvant
O	879	886	therapy
O	887	891	with
O	892	901	neratinib
O	902	909	reduces
O	910	917	disease
O	918	929	recurrences
O	930	932	in
O	933	938	Asian
O	939	944	women
O	945	949	with
O	950	954	HER2
O	954	955	-
O	955	963	positive
O	964	970	breast
O	971	977	cancer
O	977	978	.

O	979	984	Trial
O	985	997	registration
O	997	998	:
O	999	1013	Clinicaltrials
O	1013	1014	.
O	1015	1018	gov
O	1019	1030	NCT00878709
O	1030	1031	.
